CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Lactin-V +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00305227
NCT00305227Phase 2Completed

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infections

University of Washington·interventional·Posted Mar 21, 2006·Updated Apr 14, 2023

In Brief

A Phase 2 clinical trial evaluating Lactin-V and Placebo for Urinary Tract Infection. Completed, enrolled 100 participants across 1 site.

Detailed Summary

Recurrent urinary tract infections (RUTIS) continue to be a major health problem in women and are now complicated by increasing antibiotic resistance. New preventive approaches are needed. Because most women with RUTI lack the normal protective Lactobacillus (LB) in their vaginal flora, we hypothesized that restoration of LB would reduce RUTIS. In this trail, women with recent UTI are randomized to receive either LB or placebo vaginal capsules and are followed for side effects, for colonization with LB and for occurrence of RUTI over hte next four months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2006
Enrollment StartMar 1, 2006
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 20.3 years ago

Interventions

Lactin-Vdrug

Placebodrug